Drugs that contain Letrozole; Ribociclib Succinate
1. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(5 years from now) | |
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(6 years from now) | |
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(7 years from now) | |
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(9 years from now) | |
| CN103201275A | NOVARTIS | Salt Of 7-Cyclopentyl-2(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo [2,3-D] Pyrimidine-6-Carboxylic Acid Dimethylamide And Process Of Making Thereof |
Dec, 2015
(6 years ago) | |
| CN103788100A | NOVARTIS | Pyrrolopyrimidine Compounds As Cdk Inhibitors |
Jun, 2017
(5 years ago) | |
| CN101594871A | NOVARTIS | Pyrrolopyrimidine Compounds And Use Thereof |
May, 2027
(4 years from now) | |
| CN101594871B | NOVARTIS | Pyrrolopyrimidine Compounds And Use Thereof |
May, 2027
(4 years from now) | |
| CN102186856B | NOVARTIS | Pyrrolopyrimidine Compounds As Cdk Inhibitors |
Aug, 2029
(6 years from now) | |
| CN102186856A | NOVARTIS | Pyrrolopyrimidine Compounds As Cdk Inhibitors |
Aug, 2029
(6 years from now) | |
| CN105384741A | NOVARTIS | Salt Of Cell Cycle Regulatory Proteins Cyclin-Dependent Kinase Inhibitor And Preparation Method Thereof |
Nov, 2031
(9 years from now) | |
| CN105384741B | NOVARTIS | A Salt Of A Cell Cycle Regulation Protein Dependent Kinase Inhibitor And Preparation Method Thereof |
Nov, 2031
(9 years from now) | |
| IN200809406P1 | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
May, 2027
(4 years from now) | |
| IN283133B | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
May, 2027
(4 years from now) | |
| EP2029145A2 | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
May, 2027
(4 years from now) | |
| EP2029145B1 | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
May, 2027
(4 years from now) | |
| EP2331547A1 | NOVARTIS | Pyrrolopyrimidine Compounds As Cdk Inhibitors |
Aug, 2029
(6 years from now) | |
| EP2331547B1 | NOVARTIS | Pyrrolopyrimidine Compounds As Cdk Inhibitors |
Aug, 2029
(6 years from now) | |
| EP2638030B1 | NOVARTIS | Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof |
Nov, 2031
(9 years from now) | |
| EP2638030A1 | NOVARTIS | Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof |
Nov, 2031
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(6 years from now) | |
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(7 years from now) | |
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(9 years from now) | |
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(13 years from now) | |
Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG;EQ 200MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.